Autologous Bone Marrow Transplantation - Blog Science Connections

684 Peripheral Stem Cell Transplants
Table 2. Hematopoietic Recovery Level, Day Following Autologous Peripheral
Stem Cell Transplantation
Granulocytes 10 g/dl Platelets Platelets
Patient 1st WBC >500 mm3 Hg >20,000 mm3 >50,000 mm3
1 8 — — — —
2 8 17 34 — 70
3 11 37 47 25 59
4 7 16 23 15 32
5 9 58 58 36 48
6 8 26 26 25 45
7 9 27 21 21 49
8 9 — — — —
9 7 19 14 14 21
10 8 11 11 — 25
effective trilineage engraftment; bone marrow examined at autopsy showed
all cell lines were present. Characteristics of hematopoietic recovery are listed
in Table 2. Patient deaths were recorded on days 12,12,104,156, and 425
following transplantation. Surviving patients are alive 25, 36, 130, 263, and
445 days following transplantation.
DISCUSSION
This study demonstrates that nonleukemic cryopreserved autologous
peripheral stem cells collected while marrow function was in a relatively
steady state durably restored hematopoiesis following marrow-ablative therapy.
Because each patient received autologous cells, regeneration of marrow
rather than engraftment by peripheral stem cells cannot be disproved, but no
explanation other than engraftment of peripheral stem cells seems likely to
account for peripheral evidence of hematopoiesis at 7 days following highdose
therapy. This technique may offer patients ineligible for autologous
bone marrow transplantation, because of bone marrow metastases, prior
pelvic radiation, or excessive anesthetic risks, the opportunity to receive
marrow-ablative high-dose cytotoxic therapy.
REFERENCES
1. Goodman JW, Hodgson GS. Blood 1962;19:702.
2. McCredie KB, Hersh EM, Freireich EJ. Science 1971 ;171:293.
3. Scarpel SC, Zander AR, Harvath L, Epstein RB. Exp Hematol 1979;7:113.
4. Lasky LC, Ash RC, Kersey JH, Zanjani ED, McCullough J. Blood 1982;59:822.